Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs).
Sunitinib also inhibits CD117 (c-KIT),[REF] the receptor tyrosine kinase that (when improperly activated by mutation) drives the majority of gastrointestinal stromal cell tumors [REF].